Y-mAbs Therapeutics Inc (YMAB)
10.10
-0.44
(-4.17%)
USD |
NASDAQ |
Nov 21, 16:00
9.95
-0.15
(-1.49%)
Pre-Market: 08:26
Y-mAbs Therapeutics Enterprise Value: 384.25M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 384.25M |
| November 20, 2024 | 403.96M |
| November 19, 2024 | 418.29M |
| November 18, 2024 | 412.02M |
| November 15, 2024 | 430.83M |
| November 14, 2024 | 450.98M |
| November 13, 2024 | 522.20M |
| November 12, 2024 | 522.20M |
| November 11, 2024 | 597.89M |
| November 08, 2024 | 625.21M |
| November 07, 2024 | 628.35M |
| November 06, 2024 | 634.62M |
| November 05, 2024 | 608.19M |
| November 04, 2024 | 597.89M |
| November 01, 2024 | 592.07M |
| October 31, 2024 | 581.44M |
| October 30, 2024 | 596.66M |
| October 29, 2024 | 591.74M |
| October 28, 2024 | 594.87M |
| October 25, 2024 | 580.10M |
| October 24, 2024 | 587.26M |
| October 23, 2024 | 597.56M |
| October 22, 2024 | 596.66M |
| October 21, 2024 | 583.68M |
| October 18, 2024 | 578.76M |
| Date | Value |
|---|---|
| October 17, 2024 | 567.57M |
| October 16, 2024 | 590.40M |
| October 15, 2024 | 572.04M |
| October 14, 2024 | 582.79M |
| October 11, 2024 | 581.00M |
| October 10, 2024 | 550.11M |
| October 09, 2024 | 561.30M |
| October 08, 2024 | 564.88M |
| October 07, 2024 | 560.40M |
| October 04, 2024 | 565.78M |
| October 03, 2024 | 537.13M |
| October 02, 2024 | 562.19M |
| October 01, 2024 | 523.25M |
| September 30, 2024 | 520.56M |
| September 27, 2024 | 499.37M |
| September 26, 2024 | 493.58M |
| September 25, 2024 | 498.04M |
| September 24, 2024 | 499.37M |
| September 23, 2024 | 504.28M |
| September 20, 2024 | 534.14M |
| September 19, 2024 | 546.17M |
| September 18, 2024 | 527.01M |
| September 17, 2024 | 559.99M |
| September 16, 2024 | 502.05M |
| September 13, 2024 | 534.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
16.48M
Minimum
Nov 03 2022
2.067B
Maximum
Dec 17 2020
721.03M
Average
556.61M
Median
Apr 03 2024
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
| Oragenics Inc | 2.273M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.998M |
| Revenue (Quarterly) | 18.46M |
| Total Expenses (Quarterly) | 27.03M |
| EPS Diluted (Quarterly) | -0.16 |
| Gross Profit Margin (Quarterly) | 87.82% |
| Profit Margin (Quarterly) | -37.91% |
| Earnings Yield | -5.35% |
| Normalized Earnings Yield | -5.346 |